BE2014C057I2 - - Google Patents

Info

Publication number
BE2014C057I2
BE2014C057I2 BE2014C057C BE2014C057C BE2014C057I2 BE 2014C057 I2 BE2014C057 I2 BE 2014C057I2 BE 2014C057 C BE2014C057 C BE 2014C057C BE 2014C057 C BE2014C057 C BE 2014C057C BE 2014C057 I2 BE2014C057 I2 BE 2014C057I2
Authority
BE
Belgium
Application number
BE2014C057C
Other languages
French (fr)
Original Assignee
Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C057(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Pharma Co filed Critical Sumitomo Pharma Co
Publication of BE2014C057I2 publication Critical patent/BE2014C057I2/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE2014C057C 2005-05-26 2014-09-17 BE2014C057I2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005153508 2005-05-26

Publications (1)

Publication Number Publication Date
BE2014C057I2 true BE2014C057I2 (en) 2025-12-10

Family

ID=37452103

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C057C BE2014C057I2 (en) 2005-05-26 2014-09-17

Country Status (22)

Country Link
US (5) US8729085B2 (en)
EP (2) EP1884242B1 (en)
JP (2) JP4733120B2 (en)
KR (2) KR101552033B1 (en)
CN (2) CN102048734B (en)
AU (1) AU2006250340C1 (en)
BE (1) BE2014C057I2 (en)
BR (2) BR122020005056B1 (en)
CA (1) CA2606510C (en)
CY (2) CY1114118T1 (en)
DK (2) DK1884242T3 (en)
ES (2) ES2408687T3 (en)
FR (1) FR14C0069I2 (en)
HU (1) HUS1400051I1 (en)
LU (1) LU92550I2 (en)
MX (1) MX2007014872A (en)
NL (1) NL300690I2 (en)
PL (1) PL1884242T3 (en)
PT (1) PT1884242E (en)
RU (1) RU2398586C3 (en)
SI (1) SI1884242T1 (en)
WO (1) WO2006126681A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5219508B2 (en) * 2005-05-18 2013-06-26 大日本住友製薬株式会社 Stable tablets containing droxidopa
DK1884242T3 (en) * 2005-05-26 2013-05-06 Dainippon Sumitomo Pharma Co PHARMACEUTICAL COMPOSITION COMPREHENSIVE LURASIDON
KR20100121483A (en) * 2008-02-11 2010-11-17 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Tablet having improved elution properties
CA2727488C (en) * 2008-06-13 2016-09-20 Dainippon Sumitomo Pharma Co., Ltd. Tablet quickly disintegrating in the oral cavity and method for producing the same
JP5694773B2 (en) * 2008-09-30 2015-04-01 テバ製薬株式会社 COMPRESSION MOLDED PREPARATION AND METHOD
BRPI1007855B1 (en) 2009-05-19 2020-03-10 Celgene Corporation Oral dosage forms comprising 4-amino-2- (2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione
EP2629775A4 (en) * 2010-10-18 2014-06-11 Dainippon Sumitomo Pharma Co EXTENDED RELEASE FORMULATION FOR INJECTION
WO2012063246A1 (en) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Amorphous form of lurasidone hydrochloride
WO2012107890A2 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
WO2012156981A1 (en) 2011-05-13 2012-11-22 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
US8981095B2 (en) 2011-07-28 2015-03-17 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
CN102911169B (en) * 2011-08-02 2015-05-06 上海医药工业研究院 Method for preparing lurasidone
WO2013061338A1 (en) 2011-08-24 2013-05-02 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
CN103446071B (en) * 2012-05-29 2017-12-19 江苏豪森药业集团有限公司 A kind of oral tablet and its production and use
CN102688209A (en) * 2012-06-21 2012-09-26 李兴惠 Lurasidone tablet and preparation method thereof
CN102688210A (en) * 2012-06-21 2012-09-26 李兴惠 Lurasidone medicine composition and preparation method
CN106074414B (en) * 2012-07-12 2019-01-18 成都康弘药业集团股份有限公司 A kind of oral disnitegration tablet and preparation method thereof containing Lurasidone
CN103006661B (en) * 2012-12-06 2015-02-18 江苏先声药物研究有限公司 Preparation containing lurasidone hydrochloride and preparation method thereof
US20150157628A1 (en) * 2013-12-11 2015-06-11 Saravanan Kannusamy Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (en) 2014-07-25 2016-01-28 Lupin Limited Oral pharmaceutical composition of lurasidone
CN104606133A (en) * 2015-01-07 2015-05-13 万特制药(海南)有限公司 Oral lurasidone suspension and preparation method thereof
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
DE102016205950A1 (en) * 2016-04-08 2017-10-12 Dietrich Seidel Means for use in inflammatory conditions of the mucous membranes
EA201991007A1 (en) * 2016-11-02 2019-08-30 Сановель Илач Санайи Ве Тиджарет А.Ш. SOLID PHARMACEUTICAL COMPOSITIONS BASED ON LURAZIDONE HYDROCHLORIDE FOR ORAL USE
CN108567758A (en) * 2017-03-08 2018-09-25 湖南洞庭药业股份有限公司 Lurasidone HCl tablet and preparation method thereof
CN111698992A (en) * 2017-08-18 2020-09-22 艾伯维公司 Pharmaceutical formulation for the treatment of endometriosis, uterine fibroids, polycystic ovarian syndrome or adenomyosis
CN107854445A (en) * 2017-12-17 2018-03-30 佛山市弘泰药物研发有限公司 A kind of Lurasidone HCl dispersible tablet and preparation method thereof
CN107875122A (en) * 2017-12-17 2018-04-06 佛山市弘泰药物研发有限公司 A kind of Lurasidone HCl self-micro emulsion formulation and preparation method thereof
CN107854446A (en) * 2017-12-19 2018-03-30 佛山市弘泰药物研发有限公司 A kind of Lurasidone HCl oral disintegrating tablet and preparation method thereof
JPWO2019167978A1 (en) 2018-02-28 2021-02-04 大日本住友製薬株式会社 Aqueous suspension-type pharmaceutical product with controlled dissolution
US20210177197A1 (en) 2018-04-10 2021-06-17 Z-Catering Mitte Gmbh Device for heating food preserved in packaging units and for group catering
WO2019199134A1 (en) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 Pharmaceutical composition comprising lenalidomide
US20230016901A1 (en) * 2019-09-25 2023-01-19 Nobelpharma Co., Ltd. Granule in which unpleasant taste is masked and method for producing granule
WO2022042646A1 (en) * 2020-08-26 2022-03-03 浙江华海药业股份有限公司 Lurasidone hydrochloride composition and preparation method therefor
AT17300U3 (en) * 2020-12-03 2022-02-15 G L Pharma Gmbh Solid oral pharmaceutical composition
MX2023007601A (en) * 2020-12-23 2023-07-10 Sumitomo Pharma Co Ltd Oral solid preparation.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en) 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US5104648A (en) 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
JP2800953B2 (en) 1990-07-06 1998-09-21 住友製薬株式会社 New imide derivatives
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
DK0812195T3 (en) 1995-02-28 2003-03-03 Aventis Pharma Inc Pharmaceutical composition for piperidinoalkanol compounds
JP4022269B2 (en) 1995-05-26 2007-12-12 協和醗酵工業株式会社 Pharmaceutical composition
CZ299018B6 (en) 1997-10-20 2008-04-02 Dainippon Sumitomo Pharma Co., Ltd. Quick-dissolving pharmaceutical preparation
JP4063386B2 (en) * 1998-01-29 2008-03-19 キッセイ薬品工業株式会社 Rapid-release oral pharmaceutical composition
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
EP1169024B1 (en) * 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
AU2001246861A1 (en) * 2000-04-10 2001-10-23 Sumitomo Pharmaceuticals Co. Ltd. Sustained release preparations
JP4868695B2 (en) * 2000-09-22 2012-02-01 大日本住友製薬株式会社 Oral preparation with good disintegration
ATE468325T1 (en) 2001-03-19 2010-06-15 Dainippon Sumitomo Pharma Co ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION CONTAINING SAME
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP1535616B1 (en) * 2002-08-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Remedy for integration dysfunction syndrome
EP1536788A1 (en) 2002-08-30 2005-06-08 Pharmacia Corporation Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
WO2004078173A1 (en) * 2003-02-05 2004-09-16 Shionogi & Co., Ltd. Tablet having improved dissolution characteristics
PT3395338T (en) 2003-09-12 2019-07-23 Amgen Inc Rapid dissolution formulation of cinacalcet hcl
CN1913876B (en) 2003-12-09 2013-06-26 大日本住友制药株式会社 Drug-containing grains and solid preparation containing the grains
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
DK1884242T3 (en) * 2005-05-26 2013-05-06 Dainippon Sumitomo Pharma Co PHARMACEUTICAL COMPOSITION COMPREHENSIVE LURASIDON

Also Published As

Publication number Publication date
RU2007148997A (en) 2009-07-10
AU2006250340A1 (en) 2006-11-30
US8883794B2 (en) 2014-11-11
MX2007014872A (en) 2008-02-15
BRPI0611409B8 (en) 2021-05-25
CN101184489B (en) 2011-01-19
BRPI0611409A8 (en) 2015-12-15
NL300690I2 (en) 2017-11-02
JP4733120B2 (en) 2011-07-27
RU2398586C2 (en) 2010-09-10
CN102048734B (en) 2013-11-20
JP5285105B2 (en) 2013-09-11
AU2006250340C1 (en) 2014-06-12
CY1114118T1 (en) 2016-06-22
FR14C0069I2 (en) 2015-11-20
RU2398586C3 (en) 2017-10-04
DK1884242T3 (en) 2013-05-06
ES2535478T3 (en) 2015-05-12
US20090143404A1 (en) 2009-06-04
US8729085B2 (en) 2014-05-20
EP2422783B1 (en) 2015-04-08
KR20080012306A (en) 2008-02-11
CN101184489A (en) 2008-05-21
US20150265611A1 (en) 2015-09-24
BRPI0611409A2 (en) 2010-11-23
BR122020005056A2 (en) 2010-11-23
DK2422783T3 (en) 2015-05-11
EP1884242A4 (en) 2009-07-01
EP2422783A1 (en) 2012-02-29
HK1108379A1 (en) 2008-05-09
BR122020005056A8 (en) 2022-11-22
JPWO2006126681A1 (en) 2008-12-25
EP1884242B1 (en) 2013-04-17
US9907794B2 (en) 2018-03-06
EP1884242A1 (en) 2008-02-06
US9555027B2 (en) 2017-01-31
CA2606510C (en) 2014-07-22
KR101380088B1 (en) 2014-04-10
WO2006126681A1 (en) 2006-11-30
LU92550I2 (en) 2015-11-02
KR101552033B1 (en) 2015-09-09
US20140235651A1 (en) 2014-08-21
BR122020005056B1 (en) 2023-01-10
CN102048734A (en) 2011-05-11
PT1884242E (en) 2013-05-21
FR14C0069I1 (en) 2014-10-24
ES2408687T3 (en) 2013-06-21
JP2011126915A (en) 2011-06-30
CY2014039I1 (en) 2016-06-22
CY2014039I2 (en) 2016-06-22
SI1884242T1 (en) 2013-07-31
PL1884242T3 (en) 2013-09-30
CA2606510A1 (en) 2006-11-30
KR20130122019A (en) 2013-11-06
US20180161322A1 (en) 2018-06-14
US20150056284A1 (en) 2015-02-26
BRPI0611409B1 (en) 2020-12-29
AU2006250340B2 (en) 2012-02-09
HUS1400051I1 (en) 2016-10-28

Similar Documents

Publication Publication Date Title
BE2025C533I2 (en)
BE2024C510I2 (en)
BE2023C529I2 (en)
BE2021C552I2 (en)
BE2021C557I2 (en)
BE2021C531I2 (en)
BE2021C524I2 (en)
BE2021C519I2 (en)
BE2021C513I2 (en)
BE2020C531I2 (en)
BE2020C511I2 (en)
BE2020C508I2 (en)
BE2020C004I2 (en)
BE2019C521I2 (en)
BE2019C503I2 (en)
BE2018C037I2 (en)
BE2018C035I2 (en)
BE2018C019I2 (en)
BE2018C016I2 (en)
BE2017C028I2 (en)
BE2019C533I2 (en)
BE2017C007I2 (en)
BE2018C028I2 (en)
BE2016C045I2 (en)
BE2016C022I2 (en)